Evidence map›Paper›PMID 37540451›Full record

ArticleCanadian journal of public health = Revue canadienne de sante publique2023

Comparison of smoking prevalence in Canada before and after nicotine vaping product access using the SimSmoke model.

David T Levy, Christopher J Cadham, Zhe Yuan, Yameng Li, Shannon Gravely, K Michael Cummings

Open access · hybridAbstract read
In one paragraph

Article in Canadian journal of public health = Revue canadienne de sante publique, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Cancer Mortality Before Age 50 Years.JAMA network open · 2026
    Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Implementing a smoke-free generation policy for Canada: estimates of the long-term impacts.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

David T LevyLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. DL777@georgetown.edu.ORCID 0000-0001-5280-3612
Christopher J CadhamDepartment of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
Zhe YuanLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Yameng LiLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Shannon GravelyDepartment of Psychology, University of Waterloo, Waterloo, ON, Canada.
K Michael CummingsDepartment of Psychiatry & Behavioral Science, Medical University of South Carolina, Charleston, SC, USA.
Georgetown University · USMedical University of South Carolina · USUniversity of Michigan · USUniversity of Waterloo · CA

Funding

Vaporized Nicotine Product Initiation Among Youth in the US, Canada, and England: Methods to Predict Uptake and Policy EfficacyP01CA200512 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FONG, GEOFFREY T · 2016 to 2025
$25.3M
NCI NIH HHS P01 CA200512
6 · The paper itself

Abstract

objectivesThe public health impact of nicotine vaping products (NVPs) is subject to complex transitions between NVP and cigarette use. To circumvent the data limitations and parameter instability challenges in modeling transitions, we indirectly estimate NVPs' impact on smoking prevalence and resulting smoking-attributable deaths using the SimSmoke simulation model.

methodsCanada SimSmoke uses age- and sex-specific data on Canadian population, smoking prevalence and tobacco control policies. The model incorporates the impact of cigarette-oriented policies on smoking prevalence but not the explicit contribution of NVPs. The model was calibrated from 1999 to 2012, thereby projecting smoking prevalence before NVPs were widely used in Canada. The NVP impact on smoking prevalence is inferred by comparing projected 2012-2020 smoking trends absent NVPs to corresponding trends from two Canadian national surveys. We further distinguish impacts before and after NVPs became regulated in 2018 and more available.

resultsComparing 2012-2020 survey data of post-NVP to SimSmoke projected smoking prevalence trends, one survey indicated an NVP-related relative reduction of 15% (15%) for males (females) age 15+, but 32% (52%) for those ages 15-24. The other survey indicated a 14% (19%) NVP-related smoking reduction for ages 18+, but 42% (53%) for persons ages 18-24. Much of the gain occurred since Canada relaxed NVP restrictions. NVP-related 2012-2020 smoking reductions yielded 100,000 smoking-attributable deaths averted from 2012 to 2060.

conclusionSmoking prevalence in Canada, especially among younger adults, declined more rapidly once NVPs became readily available. The emergence of NVPs into the Canadian marketplace has not slowed the decline in smoking.

Indexed as

Electronic Nicotine Delivery SystemsVapingAdolescentAdultCanadaFemaleHumansMaleNicotinePrevalenceSmokingNicotineCanadaE-cigarettesENDSSimulation modelSmoking

Identifiers

PMID37540451
PMCPMC10661672
OpenAlexW4385564393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.